Last reviewed · How we verify
NCT06935578: ALIGNED
RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)
trial in CADASIL in 500 participants. Currently enrolling.
19 May 2026
Quick facts
| Lead sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 May 2023 |
| Primary completion | 19 May 2026 |
| Estimated completion | 19 May 2026 |
| Sites | 17 locations across Italy |
Conditions studied
- CADASIL — all drugs for CADASIL →
- CADASIL (Diagnosis) — all drugs for CADASIL (Diagnosis) →
- Moya Moya Disease — all drugs for Moya Moya Disease →
- Moyamoya — all drugs for Moyamoya →
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta — full company profile →
Who can join
18 and older, any sex, with CADASIL or CADASIL (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebrovascular diseases (CVDs) are one leading cause of morbidity and mortality worldwide. Despite intensive investigations, more than 30% of strokes remain of undetermined origin. Rare Cerebrovascular Diseases (rCVDs), including heritable (i.e., CADASIL, COL4A1 syndrome, Fabry disease) and acquired conditions (i.e., Sneddon syndrome, Moyamoya arteriopathy) account for a proportion of these strokes. However, rCVDs are often misdiagnosed since clinicians are not able to recognize them. Although rare, the identification of these stroke causes is important to establish appropriate management measures, including genetic counselling, and, if available, therapy. The lack of data on phenotype and clinical course of rCVDs, given the paucity of published series, makes the diagnosis and the development of therapies challenging. Furthermore, the molecular characterization of rCVDs is still lacking, despite progresses achieved in common stroke by applying high throughput approaches as multi-omics. Since the diagnosis and care of rCVDs require adequate expertise and instrumental tools, clinical and research activities are usually reserved to few specialized centers, mostly located in the North of Italy, leading patients to expensive trips for consultations. Therefore, the creation of a clinical and research network aimed at improving the diagnostic pathways of rCVDs is highly needed to improve the number of patients with rCVDs to better define the clinical phenotype and to transfer the knowledge on rCVDs in other centers overall Italy filling the geographical gap affecting Southern Italy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06935578
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CADASIL
Currently open trials in the same condition.
- NCT06938100 — Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASIL · recruiting
- NCT07497867 — Long-term Prospective Study of Korean CADASIL Patients · recruiting
Other Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials
Trials by the same sponsor.
- NCT07168850 — Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia · NA · recruiting
- NCT06699095 — Home Rehabilitation As Continuity of Care in MS · NA · recruiting
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06584097 — COMparative Performance of General Purpose Models · recruiting
- NCT07427940 — Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06935578 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06935578.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing